Aptinyx Inc Stock News

Squarepoint Ops LLC reduced its stake in shares of Aptinyx Inc. (NASDAQ:APTX) by 44.1% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 34,061 shares of the companys stock after selling 26,917 shares during the period. Squarepoint Ops LLC owned approximately 0.05% of Aptinyx worth $96,000 []

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company management will participate in a fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference being held November 29, 2021 through December 2, 2021. The pre-recorded fireside chat will be available to view on the Events and Presentations page in the Inv

Aptinyx Inc. (NASDAQ:APTX) Director Robert J. Hombach purchased 5,400 shares of Aptinyx stock in a transaction dated Thursday, November 11th. The shares were purchased at an average cost of $2.40 per share, for a total transaction of $12,960.00. The purchase was disclosed in a legal filing with the SEC, which is available at this link. []

Aptinyx Inc. (NASDAQ:APTX) Director Robert J. Hombach purchased 5,400 shares of the businesss stock in a transaction on Thursday, November 11th. The stock was acquired at an average price of $2.40 per share, with a total value of $12,960.00. The transaction was disclosed in a legal filing with the SEC, which is available through the []

Aptinyx, Inc. (APTX) CEO Norbert Riedel on Q3 2021 Results - Earnings Call Transcript

EVANSTON, Ill--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, tod

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, to

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announ

Aptinyx Inc. (APTX) CEO Norbert Riedel on Q2 2021 Results - Earnings Call Transcript

APTX stock went into long-term depression following a failed trial in 2019.

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announ

When you're shopping for ground-floor biotech opportunities, it pays to be patient and diligent. APTX stock is looking good here.

After a Type C meeting with the FDA, Aptinyx Inc (NASDAQ: APTX) has finalized the design of its Phase 2b program for NYX-783 in patients with post-traumatic stress disorder (PTSD). The program wil

The stock price of Aptinyx Inc. (Nasdaq: APTX) fell by over 10% pre-market. This is why it happened.

EVANSTON, Ill.--(BUSINESS WIRE)--Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announ